BENGALURU, July 7 (Reuters) - Indian drugmaker Cipla , opens new tab said on Friday its U.S. unit was recalling six batches of albuterol sulfate inhalation aerosol due to a "container defect".

A decade ago Yusuf Hamied, chairman and managing director of Indian drugmaker Cipla (sales: $1.2 billion), earned the label of “drug pirate” for his cheap knockoffs, notably of expensive AIDS ...

Cipla has received the Food and Drug Administration’s blessing for lanreotide injection 120 mg/0.5 ml, 90 mg/0.3 ml, 60 mg/0.2 ml, which is the generic of somatuline depot (lanreotide) injection.

Drugmaker Cipla on Tuesday announced that it has entered into an exclusive licensing agreement with Taiwan-based Formosa Pharmaceuticals for the commercialization of clobetasol propionate ...

Cipla subsidiary InvaGen issued a voluntary recall of one lot of the oral anti-seizure drug vigabatrin due to problems with seal integrity in its packaging. The recalled lot of the medication ...

Cipla, which is one of the world’s largest generic drug manufacturers, was recently cited by inspectors from the U.S. Food and Drug Administration for a litany of violations at a plant in India.

Common flu, seasonal throat infections, and fevers are on the rise in India, making it imperative to practice every day self-care and community protection. Leading the charge, Cipla Health Ltd ...

Cipla laid the foundation for the Indian pharmaceutical industry in 1935, with the vision to make India self-reliant in healthcare. Over the years, Cipla has emerged as one of the most respected ...

Meanwhile, Cipla's fourth-quarter revenue of 61.63 billion rupees ($738.4 million) missed analysts' expectations of 62.41 billion rupees, per LSEG, sending its shares down as much as 3.1%.